Opyt lecheniya bol'nykh metastazami kolorektal'nogo raka: irinotekan+raltitreksed (2-ya liniya khimioterapii)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents data on the efficacy and toxicity of the combination of irinotecan and raltitrexed as 2nd line chemotherapy for colorectal cancer patients with metastases. Disease control was achieved in 79.2% of patients. The median time to progression was 4.6 months, median overall survival - 23.1. Grade 3-4 toxicity did not exceed 14%. Described mode can be considered as an alternative to standard combinations in the 2nd line chemotherapy of disseminated colorectal cancer. A case of effective application of a combination of irinotecan and raltitrexed is discussed.

Texto integral

Acesso é fechado

Bibliografia

  1. Ferlay J., Soerjomataram I., Ervik M., et al. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer.
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М., 2015. 250 с.
  3. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 году. М., 2014. 235 с.
  4. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. JCO. 1998;16:1301-308.
  5. Cunningham D., Zalcberg J., Smith I., et al. & the «Tomudex» International Study Group. «Tomudex» (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann. Oncol. 1996;7:179-82.
  6. Zalcberg J., Ibrahaim J., Johnston P., et al. ECOG phase II study of tomudex in advanced colorectal cancer. Proc. ASCO. 1997:Abstr.:951.
  7. Cocconi G., Cunningham D., Van Cutsem E., et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. JCO. 1998;2943-52.
  8. Cunningham D. Mature results from three large controlled studies with raltitrexed («Tomudex»). Br. J. Cancer. 1998;77(Suppl. 2):15-21.
  9. Desrame J., Dourthe L.M., Debourdeau P., Mille D., Albrand H. Raltitrexed in the management of metastatic colorectal cancer: The COMET study. J. Clin. Oncol. 2015;(Suppl. 3):Abstr. 677.
  10. Вахабова Ю.В., Доброва Н.В., Личиницер М.Р. Комбинация Томудекса (ралтитрексед) и Фторафура (тегафур) - новый эффективный режим химиотерапии при метастазах колоректального рака. Онкология. Национальное руководство, 2008. С. 705-10.
  11. Доброва Н.В., Вахабова Ю.В., Личиницер М.Р. Химиотерапия 1-й линии при метастазах колоректального рака: Томудекс и Фторафур. Медицинский вестник. 2008;35(462).
  12. Вахабова Ю.В. Томудекс (ралтитрексед) в составе лекарственных комбинаций при метастазах колоректального рака. Эффективность и анализ побочных эффектов. Дисс. канд. мед. наук. М., 2009.
  13. Van Cutsem E., Douillard J.Y., Köhne C.H. Toxicity of irinotecan in patients with colorectal cancer. N. Engl. J. Med. 2001;345(18):1351-52.
  14. Cunningham D., Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol. 1999;26(1 Suppl. 5);6-12.
  15. Rothenberg M.L., Cox J.V., DeVore R.F., Hainsworth J.D., Pazdur R., Rivkin S.E., Macdonald J.S., Geyer C.E. Jr, Sandbach J., Wolf D.L., Mohrland J.S., Elfring G.L., Miller L.L., Von Hoff D.D. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85(4):786-95.
  16. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;31;352(9138): 1407-12.
  17. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J. Clin. Oncol. 2004;22(2): 229-37.
  18. Pitot H.C., Rowland K.M., Sargent D.J., et al. N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. J. Clin. Oncol. (Meeting Abstracts) June 2005;23(Suppl. 16)3506.
  19. Losa F., Manzano H., Vicente P., et al. Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients. Preliminary results of a phase I/II trial. J. Clin. Oncol. (Meeting Abstracts) 2004;22(Suppl. 14):3675.
  20. Chiara S., Nobile M.T., Tomasello L., Acquati M., Taveggia P., Murolo C., Percivale P., Rosso R. Phase II Trial of Irinotecan and Raltitrexed in Chemotherapy-naive Advanced Colorectal Cancer. Anticancer Research. 2005; 25:1391-96.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies